Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Glucagon Market

Glucagon Market Trends

Report ID: GMI9179
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Glucagon Market Trends

Advancements in the pharmaceutical sector are driving innovation and progress in the development and utilization of glucagon therapies, offering numerous advantages for patients, healthcare providers, and pharmaceutical companies alike. As the prevalence of diabetes continues to rise globally, there is an increasing demand for effective treatments to manage hypoglycemic emergencies and related conditions.

Advancements in pharmaceutical technology facilitate the creation of innovative glucagon formulations, characterized by enhanced stability, bioavailability, and ease of administration. These novel drug delivery systems may encompass stable liquid formulations, alternative administration methods, or pioneering drug-device combinations like autoinjectors and microneedle patches. Such innovations aim to enhance patient convenience and foster improved treatment adherence.
Personalized medicine and precision medicine dosing enables the development of customized glucagon therapies tailored to individual patient needs. Pharmacogenomic research identifies genetic variations that influence glucagon metabolism and response, allowing for targeted therapies that optimize treatment efficacy and minimize adverse reactions.
Additionally, pharmaceutical advancements optimize manufacturing processes for glucagon products, leading to increased production efficiency, cost-effectiveness, and scalability. Process improvements may include the adoption of advanced manufacturing technologies, automation, and quality control measures, ensuring consistent product quality and supply chain reliability, thereby escalating the growth of the market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Glucagon market size was USD 422.6 million in 2023 and is expected to register 5.9% CAGR from 2024-2032 owing to the increasing prevalence of diabetes and increasing research & development activities worldwide.

Glucagon industry from the injectable segment is expected to reach USD 364.7 million by 2032 due to a rapid onset of action, typically within minutes of administration and therefore being crucial for emergency situations.

North America glucagon industry is expected to register 5.7% CAGR from 2024-2032 due to highly developed pharmaceutical industry with advanced manufacturing capabilities in the region.

Amgen Inc., Bachem Holding AG, Eli Lilly and Company, Fresenius SE & Co. KGaA, Fujifilm Holdings Corporation, Novo Nordisk A/S, Pfizer, Inc., Svar Life Science, Taj Pharmaceuticals Ltd., and Xeris Biopharma Holdings, Inc., are some of the major glucagon companies worldwide.